Company Overview

Interpharm Holdings, Inc. (formerly traded on NASDAQ under the ticker IPAH) was a U.S.-based pharmaceutical company focused primarily on the development, manufacture, and distribution of generic prescription and over-the-counter pharmaceutical products. The company operated within the generic drug manufacturing and specialty pharmaceutical industries, supplying products to wholesalers, distributors, chain pharmacies, and healthcare providers across the United States. Its revenue was primarily generated through sales of solid oral dosage generic pharmaceuticals, including tablets and capsules produced for both proprietary and contract manufacturing customers.

The company built its business around vertically integrated pharmaceutical manufacturing capabilities and regulatory compliance expertise tied to U.S. Food and Drug Administration approval processes. Interpharm expanded through acquisitions and product portfolio development during the early 2000s, positioning itself as a growing participant in the U.S. generic drug market. In 2007, Watson Pharmaceuticals, Inc. acquired Interpharm Holdings, Inc., after which the company ceased operating as an independent public entity. Public information following the acquisition became limited because the company was integrated into Watson’s broader generic pharmaceutical operations.

Business Operations

Interpharm conducted its operations primarily through subsidiaries including Interpharm, Inc. and related pharmaceutical manufacturing entities. The company’s core business involved developing abbreviated new drug applications (ANDAs), manufacturing generic pharmaceuticals, and distributing finished dosage products within the U.S. healthcare market. Revenue generation depended heavily on product approvals, manufacturing capacity utilization, customer distribution relationships, and competitive pricing within the generic drug sector.

The company’s operations were concentrated mainly in the United States, with manufacturing and corporate functions centered in New York. Interpharm controlled pharmaceutical production assets, formulation capabilities, and regulatory filings tied to approved generic products. Prior to its acquisition, the company maintained relationships with major drug wholesalers and pharmacy distribution channels. Data regarding material international joint ventures or large-scale overseas operating divisions is inconclusive based on available public sources.

Strategic Position & Investments

Interpharm’s strategic direction focused on expanding its generic pharmaceutical portfolio, increasing manufacturing scale, and improving operational efficiencies in a highly competitive market. The company pursued growth through acquisitions, product licensing arrangements, and internal product development tied to FDA-approved generic formulations. Its business model emphasized speed-to-market for generic equivalents following patent expirations of branded pharmaceuticals.

A major strategic event in the company’s history was its acquisition by Watson Pharmaceuticals, Inc. in 2007. The transaction was intended to strengthen Watson’s position in the U.S. generic pharmaceuticals market by adding manufacturing capacity and expanding its portfolio of approved and pipeline generic products. Prior to the acquisition, Interpharm invested in manufacturing infrastructure and regulatory compliance capabilities to support future product launches. Publicly available records do not indicate significant activity in emerging biotechnology sectors or advanced pharmaceutical technologies beyond conventional generic drug manufacturing.

Geographic Footprint

Interpharm’s operational footprint was concentrated primarily in the United States, where it manufactured and distributed pharmaceutical products through domestic wholesale and retail pharmaceutical channels. The company’s headquarters were located in Hauppauge, New York, and its principal manufacturing activities were also U.S.-based. Its commercial presence was tied largely to the North American generic drug market rather than broad multinational operations.

Although the company’s products may have indirectly reached international markets through distribution relationships, publicly available disclosures primarily identified Interpharm as a domestic-focused pharmaceutical manufacturer. Data regarding material operational infrastructure outside the United States is inconclusive based on available public sources.

Leadership & Governance

Interpharm Holdings, Inc. was led by executives with backgrounds in pharmaceutical manufacturing, regulatory operations, and generic drug commercialization. Leadership strategy centered on expanding the company’s generic pharmaceutical pipeline, increasing manufacturing output, and pursuing strategic acquisitions to strengthen market share in the U.S. generics industry. Governance practices reflected those of a publicly traded pharmaceutical manufacturer subject to SEC reporting requirements prior to the company’s acquisition by Watson Pharmaceuticals.

Key executives associated with the company during its final years as an independent public entity included:

• A.J. Khubani – Chairman of the Board
• Kevin P. Desharnais – Chief Executive Officer
• Richard R. Cappiello – Chief Financial Officer

Public records concerning broader executive leadership structures following the Watson acquisition are limited because Interpharm ceased operating as an independent reporting company after the transaction closed.